FCM
ICPT

Farallon Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Farallon Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-91,200
Closed -$22M – 99
2015
Q2 		$22M Buy
91,200
+5,600
+7% +$1.49M 0.3% 50
2015
Q1 		$24.1M Buy
+85,600
New +$18.5M 0.35% 49

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Farallon Capital Management's ICPT Position: Q3 2015 in Review

Farallon Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2015, closing a stake of 91,200 shares — an estimated $22M sold.

Farallon Capital Management first reported a position in ICPT in Q1 2015 and held it in 2 quarters. The position peaked at $24.1M in Q1 2015. 173 funds tracked by Wall St. Rank hold ICPT as of Q3 2015.

  • Farallon Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Farallon Capital Management sold 91,200 Intercept Pharmaceuticals, Inc. shares in Q3 2015, an estimated $22M.
  • Farallon Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • Farallon Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $24.1M in Q1 2015.
  • 173 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2015.

Based on Farallon Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.